•
Dec 31, 2023
Rigel Q4 2023 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2023.
Key Takeaways
Rigel Pharmaceuticals reported a net income of $0.7 million for the fourth quarter of 2023, with total revenues of $35.8 million driven by TAVALISSE and REZLIDHIA sales and collaboration revenues.
Net income was $0.7 million, or $0.00 per basic and diluted share.
Total revenues reached $35.8 million.
TAVALISSE net product sales increased to $25.7 million, a 17% increase compared to the same period of 2022.
REZLIDHIA net product sales were $3.9 million.
Rigel
Rigel
Forward Guidance
Rigel is focused on commercial expansion and execution, while advancing its pipeline with more strategic collaborations.